{"indexed":{"date-parts":[[2019,11,23]],"date-time":"2019-11-23T01:14:38Z","timestamp":1574471678003},"reference-count":193,"publisher":"Wiley","issue":"5","license":[{"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1","start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"delay-in-days":1981,"content-version":"tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"DOI":"10.1111\/j.1463-1326.2009.01176.x","type":"article-journal","created":{"date-parts":[[2009,11,6]],"date-time":"2009-11-06T08:46:07Z","timestamp":1257497167000},"page":"365-383","source":"Crossref","is-referenced-by-count":106,"title":"The role of adiponectin in the pathogenesis and treatment of non-alcoholic fatty liver disease","prefix":"10.1111","volume":"12","author":[{"given":"Stergios A.","family":"Polyzos","sequence":"first","affiliation":[]},{"given":"Jannis","family":"Kountouras","sequence":"additional","affiliation":[]},{"given":"Christos","family":"Zavos","sequence":"additional","affiliation":[]},{"given":"Eleni","family":"Tsiaousi","sequence":"additional","affiliation":[]}],"member":"311","published-online":{"date-parts":[[2010,3,30]]},"reference":[{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/hep.510290347","article-title":"Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease","volume":"29","author":"Caldwell","year":"1999","journal-title":"Hepatology"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/j.1365-2559.2006.02416.x","article-title":"Histological assessment of non-alcoholic fatty liver disease","volume":"49","author":"Hubscher","year":"2006","journal-title":"Histopathology"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1042\/CS20080253","article-title":"Metabolic disturbances in non-alcoholic fatty liver disease","volume":"116","author":"Byrne","year":"2009","journal-title":"Clin Sci (Lond)"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/hep.20734","article-title":"Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study","volume":"42","author":"Bedogni","year":"2005","journal-title":"Hepatology"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1365-2036.2008.03703.x","article-title":"Review article: epidemiology, pathogenesis and potential treatments of paediatric non-alcoholic fatty liver disease","volume":"28","author":"Barshop","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB6|cit6","unstructured":"Ford ES Giles WH Mokdad AH. 2004 27 2444 2449","DOI":"10.2337\/diacare.27.10.2444","doi-asserted-by":"crossref"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.cld.2004.04.006","article-title":"Insulin resistance and the pathogenesis of nonalcoholic fatty liver disease","volume":"8","author":"Choudhury","year":"2004","journal-title":"Clin Liver Dis"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2174\/156652409787847191","article-title":"Nonalcoholic fatty liver disease: the pathogenetic roles of insulin resistance and adipocytokines","volume":"72","author":"Polyzos","year":"2009","journal-title":"Curr Mol Med"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB9|cit9","unstructured":"Wilczynski NL Haynes RB. Robustness of empirical search strategies for clinical content in MEDLINE. Proceedings of the AMIA Symposium 2002 904 908"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/S0016-5085(98)70599-2","article-title":"Steatohepatitis: a tale of two \u201chits\u201d?","volume":"114","author":"Day","year":"1998","journal-title":"Gastroenterology"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.2337\/diabetes.50.8.1844","article-title":"Nonalcoholic fatty liver disease: a feature of the metabolic syndrome","volume":"50","author":"Marchesini","year":"2001","journal-title":"Diabetes"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1586\/17474124.2.5.705","article-title":"Role of nonalcoholic fatty liver disease in the development of insulin resistance and diabetes","volume":"2","author":"Gronbaek","year":"2008","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S0016-5085(99)70506-8","article-title":"Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity","volume":"116","author":"Matteoni","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1007\/s10620-008-0585-3","article-title":"Adipose tissue: the new endocrine organ? a review article","volume":"54","author":"Wozniak","year":"2009","journal-title":"Dig Dis Sci"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s00535-008-2193-6","article-title":"Liver diseases and metabolic syndrome","volume":"43","author":"Watanabe","year":"2008","journal-title":"J Gastroenterol"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB16|cit16","first-page":"1083","article-title":"Adipokine interrelationship with the liver","volume":"64","author":"Takei","year":"2006","journal-title":"Nippon Rinsho"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/j.1365-2036.2007.03586.x","article-title":"Adipokines and cytokines in non-alcoholic fatty liver disease","volume":"27","author":"Jarrar","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/j.cgh.2006.06.011","article-title":"Metabolic and adipokine profile of Chinese patients with nonalcoholic fatty liver disease","volume":"4","author":"Wong","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/hep.20280","article-title":"Beyond insulin resistance in NASH: TNF-alpha or adiponectin?","volume":"40","author":"Hui","year":"2004","journal-title":"Hepatology"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1172\/JCI200317797","article-title":"The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice","volume":"112","author":"Xu","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1152\/ajpendo.00110.2003","article-title":"Regulation of adiponectin by adipose tissue-derived cytokines: in vivo and in vitro investigations in humans","volume":"285","author":"Bruun","year":"2003","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB22|cit22","first-page":"127","article-title":"The multi-hit process and the antagonistic roles of tumor necrosis factor-alpha and adiponectin in nonalcoholic fatty liver disease","volume":"13","author":"Polyzos","year":"2009","journal-title":"Hippokratia"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.2337\/diacare.26.8.2442","article-title":"Adiponectin: more than just another fat cell hormone?","volume":"26","author":"Chandran","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB24|cit24","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1210\/en.2007-1561","article-title":"Plasma adiponectin complexes have distinct biochemical characteristics","volume":"149","author":"Schraw","year":"2008","journal-title":"Endocrinology"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB25|cit25","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.phrs.2007.09.014","article-title":"Adiponectin circulating levels: a new emerging biomarker of cardiovascular risk","volume":"56","author":"Giannessi","year":"2007","journal-title":"Pharmacol Res"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB26|cit26","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.jhep.2005.08.019","article-title":"Up-regulation of the anti-inflammatory adipokine adiponectin in acute liver failure in mice","volume":"44","author":"Wolf","year":"2006","journal-title":"J Hepatol"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB27|cit27","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1006\/bbrc.2001.5134","article-title":"Change in expression of GBP28\/adiponectin in carbon tetrachloride-administrated mouse liver","volume":"285","author":"Yoda-Murakami","year":"2001","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB28|cit28","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/nature01705","article-title":"Cloning of adiponectin receptors that mediate antidiabetic meta-bolic effects","volume":"423","author":"Yamauchi","year":"2003","journal-title":"Nature"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB29|cit29","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1210\/er.2006-0033","article-title":"Adipose tissue-derived factors: impact on health and disease","volume":"27","author":"Trujillo","year":"2006","journal-title":"Endocr Rev"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB30|cit30","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1172\/JCI29126","article-title":"Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome","volume":"116","author":"Kadowaki","year":"2006","journal-title":"J Clin Invest"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB31|cit31","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s00125-003-1074-z","article-title":"Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex","volume":"46","author":"Cnop","year":"2003","journal-title":"Diabetologia"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB32|cit32","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1038\/oby.2007.291","article-title":"Adiponectin and ghrelin levels and body size in normoglycemic Filipino, African-American, and white women","volume":"15","author":"Araneta","year":"2007","journal-title":"Obesity (Silver Spring)"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB33|cit33","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1210\/jc.2008-0425","article-title":"Associations of adiponectin, resistin, and tumor necrosis factor-alpha with insulin resistance","volume":"93","author":"Hivert","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB34|cit34","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1001\/jama.2009.976","article-title":"Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis","volume":"302","author":"Li","year":"2009","journal-title":"JAMA"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB35|cit35","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1006\/bbrc.1999.0255","article-title":"Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity","volume":"257","author":"Arita","year":"1999","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB36|cit36","first-page":"20","article-title":"Adiponectin: lowering in metabolic syndrome and independent relation to hypertriglyceridemia","volume":"48","author":"Tanianskii","year":"2008","journal-title":"Kardiologiia"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB37|cit37","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.2337\/diacare.27.10.2450","article-title":"Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes","volume":"27","author":"Shetty","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB38|cit38","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1210\/jcem.87.5.8624","article-title":"Serum adiponectin and leptin levels in patients with lipodystrophies","volume":"87","author":"Haque","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB39|cit39","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1016\/j.fertnstert.2004.11.077","article-title":"Plasma adiponectin and insulin resistance in women with polycystic ovary syndrome","volume":"83","author":"Ardawi","year":"2005","journal-title":"Fertil Steril"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB40|cit40","doi-asserted-by":"crossref","first-page":"160","DOI":"10.2143\/AC.63.2.2029522","article-title":"The association between plasma adiponectin level and hypertension","volume":"63","author":"Shankar","year":"2008","journal-title":"Acta Cardiol"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB41|cit41","doi-asserted-by":"crossref","first-page":"4733","DOI":"10.1371\/journal.pone.0004733","article-title":"Low adiponectin levels are an independent predictor of mixed and non-calcified coronary atherosclerotic plaques","volume":"4","author":"Broedl","year":"2009","journal-title":"PLoS ONE"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB42|cit42","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/MCA.0b013e3282f3c40b","article-title":"Impact of plasma adiponectin levels to the presence and severity of coronary artery disease in patients with metabolic syndrome","volume":"19","author":"Selcuk","year":"2008","journal-title":"Coron Artery Dis"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB43|cit43","first-page":"55","article-title":"Adiponectin and resistin-new hormones of white adipose tissue","volume":"9","author":"Beltowski","year":"2003","journal-title":"Med Sci Monit"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB44|cit44","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1038\/nm788","article-title":"Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase","volume":"8","author":"Yamauchi","year":"2002","journal-title":"Nat Med"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB45|cit45","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1002\/hep.21991","article-title":"High molecular weight adiponectin inhibits proliferation of hepatic stellate cells via activation of adenosine monophosphate-activated protein kinase","volume":"47","author":"Adachi","year":"2008","journal-title":"Hepatology"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB46|cit46","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.bbrc.2006.09.101","article-title":"Aldehyde oxidase 1 is highly abundant in hepatic steatosis and is downregulated by adiponectin and fenofibric acid in hepatocytes in vitro","volume":"350","author":"Neumeier","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB47|cit47","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1053\/j.gastro.2006.05.054","article-title":"Nonalcoholic fatty liver disease: Cytokine-adipokine interplay and regulation of insulin resistance","volume":"131","author":"Tilg","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB48|cit48","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jhep.2007.04.002","article-title":"Insulin resistance in hepatocytes and sinusoidal liver cells: mechanisms and consequences","volume":"47","author":"Leclercq","year":"2007","journal-title":"J Hepatol"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB49|cit49","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1111\/j.1742-4658.2009.06955.x","article-title":"Full-length adiponectin protects hepatocytes from palmitate-induced apoptosis via inhibition of c-Jun NH terminal kinase","volume":"276","author":"Jung","year":"2009","journal-title":"FEBS J"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB50|cit50","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1210\/en.2004-1572","article-title":"Regulation of T cell-mediated hepatic inflammation by adiponectin and leptin","volume":"146","author":"Sennello","year":"2005","journal-title":"Endocrinology"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB51|cit51","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1152\/ajpendo.90731.2008","article-title":"APPL1: role in adiponectin signaling and beyond","volume":"296","author":"Deepa","year":"2009","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB52|cit52","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.1210\/jc.2004-2240","article-title":"Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity","volume":"90","author":"Bugianesi","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB53|cit53","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1136\/gut.2003.037010","article-title":"Adiponectin and its receptors in non-alcoholic steatohepatitis","volume":"54","author":"Kaser","year":"2005","journal-title":"Gut"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB54|cit54","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1111\/j.1572-0241.2005.00297.x","article-title":"Hypoadiponectinemia predicts the severity of hepatic fibrosis and pancreatic Beta-cell dysfunction in nondiabetic nonobese patients with nonalcoholic steatohepatitis","volume":"100","author":"Musso","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB55|cit55","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/01.mcg.0000152747.79773.2f","article-title":"Is adiponectin involved in the pathogenesis of nonalcoholic steatohepatitis? A preliminary human study","volume":"39","author":"Vuppalanchi","year":"2005","journal-title":"J Clin Gastroenterol"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB56|cit56","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1530\/eje.1.01821","article-title":"Plasma adiponectin is decreased in nonalcoholic fatty liver disease","volume":"152","author":"Pagano","year":"2005","journal-title":"Eur J Endocrinol"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB57|cit57","doi-asserted-by":"crossref","first-page":"4287","DOI":"10.1210\/jc.2006-1010","article-title":"Alanine aminotransferase levels and fatty liver in childhood obesity: associations with insulin resistance, adiponectin, and visceral fat","volume":"91","author":"Burgert","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB58|cit58","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1016\/j.metabol.2007.06.013","article-title":"Regulation of adiponectin receptor expression in human liver and a hepatocyte cell line","volume":"56","author":"Shimizu","year":"2007","journal-title":"Metabolism"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB59|cit59","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1111\/j.1572-0241.2007.01322.x","article-title":"Usefulness of a combined evaluation of the serum adiponectin level, HOMA-IR, and serum type IV collagen 7 S level to predict the early stage of nonalcoholic steatohepatitis","volume":"102","author":"Shimada","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB60|cit60","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1007\/s11695-008-9506-y","article-title":"A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH)","volume":"18","author":"Younossi","year":"2008","journal-title":"Obes Surg"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB61|cit61","first-page":"355","article-title":"Serum adiponectin levels in different types of non alcoholic liver disease. Correlation with steatosis, necroinflammation and fibrosis.","volume":"71","author":"Arvaniti","year":"2008","journal-title":"Acta Gastro-Enterol Belg"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB62|cit62","first-page":"123","article-title":"Adipokines in a group of Mexican patients with nonalcoholic steatohepatitis","volume":"8","author":"Munoz","year":"2009","journal-title":"Ann Hepatol"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB63|cit63","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1007\/s10620-007-9981-3","article-title":"Influence of insulin resistance and adipokines in the grade of steatosis of nonalcoholic fatty liver disease","volume":"53","author":"Aller","year":"2008","journal-title":"Dig Dis Sci"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB64|cit64","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/j.1365-2265.2006.02527.x","article-title":"Associations between plasma adiponectin concentrations and liver histology in patients with nonalcoholic fatty liver disease","volume":"64","author":"Targher","year":"2006","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB65|cit65","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1080\/07853890801946515","article-title":"Association of liver disease with postprandial large intestinal triglyceride-rich lipoprotein accumulation and pro\/antioxidant imbalance in normolipidemic non-alcoholic steatohepatitis","volume":"40","author":"Musso","year":"2008","journal-title":"Ann Med"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB66|cit66","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/j.1440-1746.2008.05548.x","article-title":"Expression of adiponectin and its receptors in livers of morbidly obese patients with non-alcoholic fatty liver disease","volume":"24","author":"Ma","year":"2009","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB67|cit67","first-page":"67","article-title":"Hepatic expression of ghrelin and adiponectin and their receptors in patients with nonalcoholic fatty liver disease","volume":"7","author":"Uribe","year":"2008","journal-title":"Ann Hepatol"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB68|cit68","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1152\/ajpendo.00494.2003","article-title":"Elevated circulating adiponectin levels in liver cirrhosis are associated with reduced liver function and altered hepatic hemodynamics","volume":"287","author":"Tietge","year":"2004","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB69|cit69","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1365-2796.2005.01543.x","article-title":"Circulating adiponectin reflects severity of liver disease but not insulin sensitivity in liver cirrhosis","volume":"258","author":"Kaser","year":"2005","journal-title":"J Intern Med"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB70|cit70","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/j.1478-3231.2004.0986.x","article-title":"Elevated plasma adiponectin concentrations in patients with liver cirrhosis correlate with plasma insulin levels","volume":"25","author":"Sohara","year":"2005","journal-title":"Liver Int"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB71|cit71","author":"Polyzos","year":"2009","article-title":"Non-linear distribution of adiponectin in patients with nonalcoholic fatty liver disease limits its use in linear regression analysis","journal-title":"J Clin Gastroenterol"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB72|cit72","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1111\/j.1572-0241.2008.01888.x","article-title":"Plasma adiponectin levels in primary biliary cirrhosis: a novel perspective for link between hypercholesterolemia and protection against atherosclerosis","volume":"103","author":"Floreani","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB73|cit73","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.jhep.2004.12.024","article-title":"High adiponectin in chronic liver disease and cholestasis suggests biliary route of adiponectin excretion in vivo","volume":"42","author":"Tacke","year":"2005","journal-title":"J Hepatol"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB74|cit74","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1517\/14728220802658481","article-title":"Paradoxical role for adiponectin in chronic renal diseases? An example of reverse epidemiology","volume":"13","author":"Beige","year":"2009","journal-title":"Expert Opin Ther Targets"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB75|cit75","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.nut.2008.07.020","article-title":"Circulating adipokines and the protective effects of hyperinsulinemia in inflammatory bowel disease","volume":"25","author":"Valentini","year":"2009","journal-title":"Nutrition"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB76|cit76","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1136\/ard.2008.095737","article-title":"Increased serum adiponectin levels in female patients with erosive compared with non-erosive osteoarthritis","volume":"68","author":"Filkova","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB77|cit77","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s10067-008-1074-y","article-title":"Serum adiponectin concentrations correlate with severity of rheumatoid arthritis evaluated by extent of joint destruction","volume":"28","author":"Ebina","year":"2009","journal-title":"Clin Rheumatol"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB78|cit78","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1016\/j.clinbiochem.2009.02.023","article-title":"Prognostic value of increased adiponectin plasma concentrations in patients with acute destabilized heart failure","volume":"42","author":"Dieplinger","year":"2009","journal-title":"Clin Biochem"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB79|cit79","author":"Celik","year":"2009","article-title":"Elevated adiponectin levels in patients with chronic heart failure: An independent predictor of mortality or a marker of cardiac cachexia?","journal-title":"Int J Cardiol"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB80|cit80","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1093\/eurjhf\/hfp046","article-title":"Adiponectin is increased in cardiac cachexia irrespective of body mass index","volume":"11","author":"Paulo","year":"2009","journal-title":"Eur J Heart Fail"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB81|cit81","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1046\/j.1365-2249.2003.02264.x","article-title":"Circulating adiponectin levels during human endotoxaemia","volume":"134","author":"Keller","year":"2003","journal-title":"Clin Exp Immunol"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB82|cit82","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s11695-008-9701-x","article-title":"Pattern of expression of adiponectin receptors in human liver and its relation to nonalcoholic steatohepatitis","volume":"19","author":"Nannipieri","year":"2009","journal-title":"Obes Surg"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB83|cit83","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1002\/hep.22142","article-title":"Adiponectin gene polymorphisms modulate acute adiponectin response to dietary fat: Possible pathogenetic role in NASH","volume":"47","author":"Musso","year":"2008","journal-title":"Hepatology"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB84|cit84","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1007\/s00535-009-0085-z","article-title":"Influence of adiponectin gene polymorphisms in Japanese patients with non-alcoholic fatty liver disease","volume":"44","author":"Tokushige","year":"2009","journal-title":"J Gastroenterol"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB85|cit85","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1007\/BF03345657","article-title":"Correlation between adiponectin polymorphisms and non-alcoholic fatty liver disease with or without metabolic syndrome in Chinese population","volume":"31","author":"Wang","year":"2008","journal-title":"J Endocrinol Invest"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB86|cit86","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/j.1478-3231.2007.01623.x","article-title":"Effect of peroxisome proliferator-activated receptors-gamma and co-activator-1alpha genetic polymorphisms on plasma adiponectin levels and susceptibility of non-alcoholic fatty liver disease in Chinese people","volume":"28","author":"Hui","year":"2008","journal-title":"Liver Int"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB87|cit87","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1002\/hep.22659","article-title":"Transcription factor 7-like 2 polymorphism modulates glucose and lipid homeostasis, adipokine profile, and hepatocyte apoptosis in NASH","volume":"49","author":"Musso","year":"2009","journal-title":"Hepatology"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB88|cit88","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1471-2350-10-15","article-title":"Association between TCF7L2 gene polymorphisms and susceptibility to type 2 diabetes mellitus: a large Human Genome Epidemiology (HuGE) review and meta-analysis","volume":"10","author":"Tong","year":"2009","journal-title":"BMC Med Genet"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB89|cit89","doi-asserted-by":"crossref","first-page":"353","DOI":"10.4158\/EP.10.4.353","article-title":"American Association of Clinical Endocrinologists protocol for standardized production of clinical practice guidelines","volume":"10","author":"AACE Ad Hoc Task Force","year":"2004","journal-title":"Endocr Pract"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB90|cit90","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.jhep.2007.03.020","article-title":"Hypoadiponectinemia accelerates hepatic tumor formation in a nonalcoholic steatohepatitis mouse model","volume":"47","author":"Kamada","year":"2007","journal-title":"J Hepatol"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB91|cit91","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1002\/hep.23046","article-title":"Adipokines in liver diseases","volume":"50","author":"Marra","year":"2009","journal-title":"Hepatology"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB92|cit92","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1097\/MCG.0b013e3181962de8","article-title":"Visceral Obesity and Hypoadiponectinemia are Significant Determinants of Hepatic Dysfunction: An Epidemiologic Study of 3827 Japanese Subjects","volume":"43","author":"Kamada","year":"2009","journal-title":"J Clin Gastroenterol"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB93|cit93","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1381\/096089206778392149","article-title":"Gene expression of leptin, resistin, and adiponectin in the white adipose tissue of obese patients with non-alcoholic fatty liver disease and insulin resistance","volume":"16","author":"Baranova","year":"2006","journal-title":"Obes Surg"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB94|cit94","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1093\/ajcn\/87.2.295","article-title":"Increased fat accumulation in liver may link insulin resistance with subcutaneous abdominal adipocyte enlargement, visceral adiposity, and hypoadiponectinemia in obese individuals","volume":"87","author":"Koska","year":"2008","journal-title":"Am J Clin Nutr"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB95|cit95","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1007\/s00125-008-1135-4","article-title":"Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon?","volume":"51","author":"Targher","year":"2008","journal-title":"Diabetologia"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB96|cit96","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1210\/jc.2007-0187","article-title":"Postprandial lipemia associates with liver fat content","volume":"92","author":"Matikainen","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB97|cit97","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1002\/hep.20896","article-title":"Adipokines in NASH: postprandial lipid metabolism as a link between adiponectin and liver disease","volume":"42","author":"Musso","year":"2005","journal-title":"Hepatology"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB98|cit98","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0929-6646(09)60079-6","article-title":"The clinical implications of blood adiponectin in cardiometabolic disorders","volume":"108","author":"Chang","year":"2009","journal-title":"J Formos Med Assoc"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB99|cit99","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1136\/gut.2003.027086","article-title":"Increased prevalence of fatty liver in arterial hypertensive patients with normal liver enzymes: role of insulin resistance","volume":"53","author":"Donati","year":"2004","journal-title":"Gut"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB100|cit100","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1097\/HJH.0b013e32830dfe4b","article-title":"Nonalcoholic fatty liver disease, adiponectin and insulin resistance in dipper and nondipper essential hypertensive patients","volume":"26","author":"Fallo","year":"2008","journal-title":"J Hypertens"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB101|cit101","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/HJH.0b013e328317a7bb","article-title":"High-normal blood pressure is associated with a cluster of cardiovascular and metabolic risk factors: a population-based study","volume":"27","author":"Bo","year":"2009","journal-title":"J Hypertens"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB102|cit102","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.numecd.2008.12.007","article-title":"Non-alcoholic fatty liver disease is associated with left ventricular diastolic dysfunction in essential hypertension","volume":"19","author":"Fallo","year":"2009","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB103|cit103","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1038\/sj.jhh.1002148","article-title":"Hypertension and fatty liver: guilty by association?","volume":"21","author":"Brookes","year":"2007","journal-title":"J Hum Hypertens"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB104|cit104","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.metabol.2004.11.008","article-title":"Exercise training is not associated with improved levels of C-reactive protein or adiponectin","volume":"54","author":"Marcell","year":"2005","journal-title":"Metabolism"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB105|cit105","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.metabol.2007.03.009","article-title":"In the absence of weight loss, exercise training does not improve adipokines or oxidative stress in overweight children","volume":"56","author":"Kelly","year":"2007","journal-title":"Metabolism"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB106|cit106","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1001\/jama.289.14.1799","article-title":"Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial","volume":"289","author":"Esposito","year":"2003","journal-title":"JAMA"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB107|cit107","doi-asserted-by":"crossref","first-page":"509","DOI":"10.3945\/ajcn.2008.26371","article-title":"Association of 1-y changes in diet pattern with cardiovascular disease risk factors and adipokines: results from the 1-y randomized Oslo Diet and Exercise Study","volume":"89","author":"Jacobs","year":"2009","journal-title":"Am J Clin Nutr"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB108|cit108","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1097\/HJR.0b013e3282efaf50","article-title":"The anti-inflammatory effects of exercise training in patients with type 2 diabetes mellitus","volume":"14","author":"Kadoglou","year":"2007","journal-title":"Eur J Cardiovasc Prev Rehabil"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB109|cit109","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.metabol.2005.01.033","article-title":"Effects of diet and\/or exercise on the adipocytokine and inflammatory cytokine levels of postmenopausal women with type 2 diabetes","volume":"54","author":"Giannopoulou","year":"2005","journal-title":"Metabolism"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB110|cit110","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/hep.22575","article-title":"Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial","volume":"49","author":"Harrison","year":"2009","journal-title":"Hepatology"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB111|cit111","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S0140-6736(05)66374-X","article-title":"Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study","volume":"365","author":"Van Gaal","year":"2005","journal-title":"Lancet"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB112|cit112","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1001\/jama.295.7.761","article-title":"Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial","volume":"295","author":"Pi-Sunyer","year":"2006","journal-title":"JAMA"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB113|cit113","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1056\/NEJMoa044537","article-title":"Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia","volume":"353","author":"Despres","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB114|cit114","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1016\/S0140-6736(06)69571-8","article-title":"Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study","volume":"368","author":"Scheen","year":"2006","journal-title":"Lancet"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB115|cit115","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1111\/j.1464-5491.2005.01569.x","article-title":"Sibutramine improves insulin sensitivity without alteration of serum adiponectin in obese subjects with Type 2 diabetes","volume":"22","author":"Hung","year":"2005","journal-title":"Diabet Med"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB116|cit116","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jnutbio.2007.05.007","article-title":"Effect of weight loss on some serum cytokines in human obesity: increase in IL-10 after weight loss","volume":"19","author":"Jung","year":"2008","journal-title":"J Nutr Biochem"},{"issue":"Suppl. 1","key":"10.1111\/j.1463-1326.2009.01176.x-BIB117|cit117","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.diabres.2003.12.008","article-title":"Sibutramine improves fat distribution and insulin resistance, and increases serum adiponectin levels in Korean obese nondiabetic premenopausal women","volume":"66","author":"Kim","year":"2004","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB118|cit118","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.metabol.2003.11.022","article-title":"Modest weight loss and reduction in waist circumference after medical treatment are associated with favorable changes in serum adipocytokines","volume":"53","author":"Valsamakis","year":"2004","journal-title":"Metabolism"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB119|cit119","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s11695-008-9678-5","article-title":"GLP-1 and adiponectin: effect of weight loss after dietary restriction and gastric bypass in morbidly obese patients with normal and abnormal glucose metabolism","volume":"19","author":"De Carvalho","year":"2009","journal-title":"Obes Surg"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB120|cit120","doi-asserted-by":"crossref","first-page":"4276","DOI":"10.1210\/jc.2007-1370","article-title":"Effects of weight loss after bariatric surgery for morbid obesity on vascular endothelial growth factor-A, adipocytokines, and insulin","volume":"93","author":"Garcia de la","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB121|cit121","doi-asserted-by":"crossref","first-page":"735","DOI":"10.2337\/db06-1161","article-title":"Increases in adiponectin predict improved liver, but not peripheral, insulin sensitivity in severely obese women during weight loss","volume":"56","author":"Lin","year":"2007","journal-title":"Diabetes"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB122|cit122","first-page":"1266","article-title":"Increase in high molecular weight adiponectin by bariatric surgery-induced weight loss","volume":"10","author":"Linscheid","year":"2008","journal-title":"Diabetes Obes Metab"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB123|cit123","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.soard.2008.08.013","article-title":"Response of adiponectin and its receptors to changes in metabolic state after gastric bypass surgery: dissociation between adipose tissue expression and circulating levels","volume":"5","author":"Savu","year":"2009","journal-title":"Surg Obes Relat Dis"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB124|cit124","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1056\/NEJMoa060326","article-title":"A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis","volume":"355","author":"Belfort","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB125|cit125","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.cgh.2006.05.005","article-title":"Changes in serum adipokine levels during pioglitazone treatment for nonalcoholic steatohepatitis: relationship to histological improvement","volume":"4","author":"Lutchman","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB126|cit126","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1053\/j.gastro.2008.03.078","article-title":"Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial","volume":"135","author":"Ratziu","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB127|cit127","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.2337\/diabetes.53.8.2169","article-title":"Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes","volume":"53","author":"Tiikkainen","year":"2004","journal-title":"Diabetes"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB128|cit128","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/j.1365-2265.2006.02658.x","article-title":"Effects of pioglitazone and metformin on plasma adiponectin in newly detected type 2 diabetes mellitus","volume":"65","author":"Sharma","year":"2006","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB129|cit129","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/j.1365-2265.2006.02723.x","article-title":"Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus","volume":"66","author":"Kim","year":"2007","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB130|cit130","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.metabol.2007.03.018","article-title":"Both slow-release and regular-form metformin improve glycemic control without altering plasma visfatin level in patients with type 2 diabetes mellitus","volume":"56","author":"Hsieh","year":"2007","journal-title":"Metabolism"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB131|cit131","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/j.metabol.2008.07.030","article-title":"Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia","volume":"57","author":"Hyogo","year":"2008","journal-title":"Metabolism"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB132|cit132","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.atherosclerosis.2006.08.028","article-title":"Increase in circulating levels of adiponectin after treatment with statin and fibrate in patients with coronary artery disease and hyperlipidemia","volume":"193","author":"Nakamura","year":"2007","journal-title":"Atherosclerosis"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB133|cit133","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/MCG.0b013e31815591aa","article-title":"Highly purified eicosapentaenoic acid treatment improves nonalcoholic steatohepatitis","volume":"42","author":"Tanaka","year":"2008","journal-title":"J Clin Gastroenterol"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB134|cit134","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1210\/jc.2005-1231","article-title":"Quinapril treatment increases insulin-stimulated endothelial function and adiponectin gene expression in patients with type 2 diabetes","volume":"91","author":"Hermann","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB135|cit135","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1440-1797.2007.00764.x","article-title":"Effect of antihypertensive agents on plasma adiponectin levels in hypertensive patients with metabolic syndrome","volume":"12","author":"Yilmaz","year":"2007","journal-title":"Nephrology (Carlton)"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB136|cit136","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1161\/01.HYP.0000078490.59735.6E","article-title":"Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension","volume":"42","author":"Furuhashi","year":"2003","journal-title":"Hypertension"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB137|cit137","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/j.1365-2710.2007.00820.x","article-title":"Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone","volume":"32","author":"Derosa","year":"2007","journal-title":"J Clin Pharm Ther"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB138|cit138","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1016\/j.metabol.2006.07.025","article-title":"The effect of spironolactone on circulating adipocytokines in patients with type 2 diabetes mellitus complicated by diabetic nephropathy","volume":"55","author":"Matsumoto","year":"2006","journal-title":"Metabolism"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB139|cit139","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1152\/ajpendo.00133.2006","article-title":"Effects of insulin therapy on liver fat content and hepatic insulin sensitivity in patients with type 2 diabetes","volume":"292","author":"Juurinen","year":"2007","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB140|cit140","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.physbeh.2007.03.004","article-title":"Effects of very low calorie diet induced body weight loss with or without human pegylated recombinant leptin treatment on changes in ghrelin and adiponectin concentrations","volume":"91","author":"Lejeune","year":"2007","journal-title":"Physiol Behav"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB141|cit141","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ghir.2006.10.001","article-title":"The effects of recombinant human growth hormone (rhGH) supplementation on adipokines and C-reactive protein in obese subjects","volume":"17","author":"Albert","year":"2007","journal-title":"Growth Horm IGF Res"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB142|cit142","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.2337\/diabetes.54.8.2390","article-title":"Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial","volume":"54","author":"Wynne","year":"2005","journal-title":"Diabetes"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB143|cit143","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1097\/HJH.0b013e328311cf37","article-title":"Central sympatholytic therapy has anti-inflammatory properties in hypertensive postmenopausal women","volume":"26","author":"Poyhonen-Alho","year":"2008","journal-title":"J Hypertens"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB144|cit144","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1016\/j.amjhyper.2005.05.026","article-title":"Blockade of sympathetic nervous system activity by rilmenidine increases plasma adiponectin concentration in patients with essential hypertension","volume":"18","author":"Nowak","year":"2005","journal-title":"Am J Hypertens"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB145|cit145","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1111\/j.1478-3231.2009.02037.x","article-title":"Effects of ursodeoxycholic acid in combination with vitamin E on adipokines and apoptosis in patients with nonalcoholic steatohepatitis","volume":"29","author":"Balmer","year":"2009","journal-title":"Liver Int"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB146|cit146","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1053\/j.gastro.2008.06.047","article-title":"Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis","volume":"135","author":"Aithal","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB147|cit147","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/MOG.0b013e3283294a18","article-title":"Recent advances in nonalcoholic fatty liver disease","volume":"25","author":"Cheung","year":"2009","journal-title":"Curr Opin Gastroenterol"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB148|cit148","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/hep.22603","article-title":"Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: selected practical issues in their evaluation and management","volume":"49","author":"Vuppalanchi","year":"2009","journal-title":"Hepatology"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB149|cit149","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1055\/s-0028-1091984","article-title":"Current and emerging therapies in nonalcoholic fatty liver disease","volume":"28","author":"Kashi","year":"2008","journal-title":"Semin Liver Dis"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB150|cit150","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1111\/j.1478-3231.2007.01574.x","article-title":"Clinicopathological improvement of non-alcoholic steatohepatitis associated with weight loss during a 14-year follow-up period","volume":"27","author":"Nishide","year":"2007","journal-title":"Liver Int"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB151|cit151","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/j.1365-2265.2004.02101.x","article-title":"Effect of dieting on plasma leptin, soluble leptin receptor, adiponectin and resistin levels in healthy volunteers","volume":"61","author":"Wolfe","year":"2004","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB152|cit152","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1385\/ENDO:26:1:065","article-title":"Lack of increase of serum adiponectin concentrations with a moderate weight loss during six months on a high-caloric diet in military service among a young male Finnish population","volume":"26","author":"Mousavinasab","year":"2005","journal-title":"Endocrine"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB153|cit153","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB154|cit154","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1053\/j.gastro.2008.02.077","article-title":"Diagnosis and therapy of nonalcoholic steatohepatitis","volume":"134","author":"Torres","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB155|cit155","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1172\/JCI25076","article-title":"Food for thought: endocannabinoid modulation of lipogenesis","volume":"115","author":"Lichtman","year":"2005","journal-title":"J Clin Invest"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB156|cit156","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/hep.21641","article-title":"Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa\/fa rats","volume":"46","author":"Gary-Bobo","year":"2007","journal-title":"Hepatology"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB157|cit157","doi-asserted-by":"crossref","first-page":"993","DOI":"10.2353\/ajpath.2008.070720","article-title":"Prevention of hepatic fibrosis in a murine model of metabolic syndrome with nonalcoholic steatohepatitis","volume":"173","author":"DeLeve","year":"2008","journal-title":"Am J Pathol"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB158|cit158","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/sj.bjp.0707511","article-title":"CB2 receptors as new therapeutic targets for liver diseases","volume":"153","author":"Lotersztajn","year":"2008","journal-title":"Br J Pharmacol"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB159|cit159","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1185\/030079905X38132","article-title":"A review of the metabolic effects of sibutramine","volume":"21","author":"Filippatos","year":"2005","journal-title":"Curr Med Res Opin"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB160|cit160","first-page":"189","article-title":"The effects of sibutramine and orlistat on the ultrasonographic findings, insulin resistance and liver enzyme levels in obese patients with non-alcoholic steatohepatitis","volume":"12","author":"Sabuncu","year":"2003","journal-title":"Rom J Gastroenterol"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB161|cit161","first-page":"364","article-title":"Nonalcoholic fatty liver disease in severely obese individuals: the influence of bariatric surgery","volume":"7","author":"De Andrade","year":"2008","journal-title":"Ann Hepatol"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB162|cit162","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1016\/j.cgh.2008.08.012","article-title":"Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis","volume":"6","author":"Mummadi","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB163|cit163","doi-asserted-by":"crossref","first-page":"12152","DOI":"10.1074\/jbc.M311113200","article-title":"Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity","volume":"279","author":"Pajvani","year":"2004","journal-title":"J Biol Chem"},{"issue":"Suppl. 1","key":"10.1111\/j.1463-1326.2009.01176.x-BIB164|cit164","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2337\/diabetes.53.2007.S43","article-title":"The biology of peroxisome proliferator-activated receptors: relationship with lipid metabolism and insulin sensitivity","volume":"53","author":"Ferre","year":"2004","journal-title":"Diabetes"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB165|cit165","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1074\/jbc.M505311200","article-title":"Mice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to peroxisome proliferator-activated receptor gamma agonists","volume":"281","author":"Nawrocki","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB166|cit166","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S1542-3565(04)00457-4","article-title":"A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis","volume":"2","author":"Sanyal","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB167|cit167","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/hep.21661","article-title":"The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis","volume":"46","author":"Lutchman","year":"2007","journal-title":"Hepatology"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB168|cit168","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1517\/14740330802597821","article-title":"How safe is the use of thiazolidinediones in clinical practice?","volume":"8","author":"Rizos","year":"2009","journal-title":"Expert Opin Drug Saf"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB169|cit169","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1038\/79697","article-title":"Metformin reverses fatty liver disease in obese, leptin-deficient mice","volume":"6","author":"Lin","year":"2000","journal-title":"Nat Med"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB170|cit170","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1111\/j.1572-0241.2005.41583.x","article-title":"A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease","volume":"100","author":"Bugianesi","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB171|cit171","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/S0140-6736(01)06042-1","article-title":"Metformin in non-alcoholic steatohepatitis","volume":"358","author":"Marchesini","year":"2001","journal-title":"Lancet"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB172|cit172","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1365-2036.2004.02025.x","article-title":"Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial","volume":"20","author":"Nair","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB173|cit173","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/j.1365-2036.2004.01888.x","article-title":"Metformin in the treatment of patients with non-alcoholic steatohepatitis","volume":"19","author":"Uygun","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB174|cit174","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1399-5448.2008.00450.x","article-title":"Treatment of non-alcoholic fatty liver disease with metformin versus lifestyle intervention in insulin-resistant adolescents","volume":"10","author":"Nadeau","year":"2009","journal-title":"Pediatr Diabetes"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB175|cit175","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3132\/dvdr.2008.027","article-title":"Metformin therapy and clinical uses.","volume":"5","author":"Scarpello","year":"2008","journal-title":"Diab Vasc Dis Res"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB176|cit176","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1111\/j.1365-2036.2006.02926.x","article-title":"A pilot study of atorvastatin treatment in dyslipemid, non-alcoholic fatty liver patients","volume":"23","author":"Gomez-Dominguez","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB177|cit177","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jhep.2007.02.013","article-title":"Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study","volume":"47","author":"Ekstedt","year":"2007","journal-title":"J Hepatol"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB178|cit178","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/j.1742-1241.2007.01666.x","article-title":"Weight loss, dietary advice and statin therapy in non-alcoholic fatty liver disease: a retrospective study","volume":"62","author":"Riley","year":"2008","journal-title":"Int J Clin Pract"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB179|cit179","first-page":"102","article-title":"PPAR agonists treatment is effective in a nonalcoholic fatty liver disease animal model by modulating fatty-acid metabolic enzymes","volume":"23","author":"Seo","year":"2008","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB180|cit180","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/S0168-8278(99)80243-8","article-title":"A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis","volume":"31","author":"Basaranoglu","year":"1999","journal-title":"J Hepatol"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB181|cit181","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1152\/ajpendo.00340.2006","article-title":"Bezafibrate regulates the expression and enzyme activity of 11beta-hydroxysteroid dehydrogenase type 1 in murine adipose tissue and 3T3-L1 adipocytes","volume":"292","author":"Nakano","year":"2007","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB182|cit182","doi-asserted-by":"crossref","first-page":"6395","DOI":"10.3748\/wjg.14.6395","article-title":"Effects of n-3 polyunsaturated fatty acids from seal oils on nonalcoholic fatty liver disease associated with hyperlipidemia","volume":"14","author":"Zhu","year":"2008","journal-title":"World J Gastroenterol"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB183|cit183","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1002\/hep.20420","article-title":"Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis","volume":"40","author":"Yokohama","year":"2004","journal-title":"Hepatology"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB184|cit184","doi-asserted-by":"crossref","first-page":"322","DOI":"10.3748\/wjg.v12.i2.322","article-title":"Inhibitory effect of angiotensin II receptor antagonist on hepatic stellate cell activation in non-alcoholic steatohepatitis","volume":"12","author":"Yokohama","year":"2006","journal-title":"World J Gastroenterol"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB185|cit185","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.atherosclerosis.2009.01.026","article-title":"Losartan reduces liver expression of plasminogen activator inhibitor-1 (PAI-1) in a high fat-induced rat nonalcoholic fatty liver disease model","volume":"206","author":"Rosselli","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB186|cit186","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1161\/HYPERTENSIONAHA.108.112292","article-title":"Olmesartan prevents cardiovascular injury and hepatic steatosis in obesity and diabetes, accompanied by apoptosis signal regulating kinase-1 inhibition","volume":"52","author":"Yamamoto","year":"2008","journal-title":"Hypertension"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB187|cit187","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/j.1440-1681.2008.05129.x","article-title":"Angiotensin converting enzyme inhibitors improve hepatic steatosis by modulating expression of tumor necrosis factor-alpha, interleukin-6 and adiponectin receptor-2 in rats with type 2 diabetes","volume":"36","author":"Zhang","year":"2009","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB188|cit188","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1055\/s-2008-1027411","article-title":"Adalimumab could suppress the activity of non alcoholic steatohepatitis (NASH)","volume":"46","author":"Schramm","year":"2008","journal-title":"Z Gastroenterol"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB189|cit189","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1136\/ard.2005.040857","article-title":"No change of serum levels of leptin and adiponectin during anti-tumour necrosis factor antibody treatment with adalimumab in patients with rheumatoid arthritis","volume":"65","author":"Harle","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB190|cit190","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.mehy.2008.12.019","article-title":"Insulin resistance and therapy: cross-talk between phosphatidylinositol-3 kinase and mitogen-activated protein kinase pathways","volume":"72","author":"Polyzos","year":"2009","journal-title":"Med Hypotheses"},{"issue":"Suppl. 7","key":"10.1111\/j.1463-1326.2009.01176.x-BIB191|cit191","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1038\/ijo.2008.235","article-title":"Gastrointestinal satiety signals","volume":"32","author":"Chaudhri","year":"2008","journal-title":"Int J Obes (Lond)"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB192|cit192","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1097\/MPG.0b013e31818e04d1","article-title":"Pharmacological interventions for nonalcoholic fatty liver disease in adults and in children: a systematic review","volume":"48","author":"Socha","year":"2009","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1111\/j.1463-1326.2009.01176.x-BIB193|cit193","author":"Angelico","first-page":"CD005166","year":"2007","article-title":"Drugs improving insulin resistance for non-alcoholic fatty liver disease and\/or non-alcoholic steatohepatitis","journal-title":"Cochrane Database Syst Rev"}],"container-title":"Diabetes, Obesity and Metabolism","original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1463-1326.2009.01176.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T17:36:02Z","timestamp":1558632962000},"score":1.0,"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3,30]]},"references-count":193,"journal-issue":{"issue":"5"},"URL":"http:\/\/dx.doi.org\/10.1111\/j.1463-1326.2009.01176.x","relation":{"cites":[]},"ISSN":["1462-8902","1463-1326"],"subject":["Internal Medicine","Endocrinology, Diabetes and Metabolism","Endocrinology"]}